Researchers continue to excited about this new drug, a groundbreaking dual agonist showing significant data in early trials for weight loss . It acts by targeting both systems: GLP-1 and GIP, which , when stimulated, help influence hunger and boost calorie burn. Early reports indicate considerable body reduction and potential advantages for patient